Pulmatrix, Inc. · NASDAQ:PULM
Pulmatrix — Investor Presentation (March 2022)
32 slides from Pulmatrix's investor presentation, Mar 29, 2022
Slide 1: Pulmatrix
PULMATRIixX NASDAQ: PULM
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements. All statements other than statements of historical fact contained herein, including statements regarding our business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected
Slide 3: Our Mission
PULM. Our M ission | PULMATRIiX is committed to the development and commercialization of novel and transformational medicines for patients all over the world, using our proprietary iSPERSE™ technology to optimally deliver both respiratory and non-respiratory therapies via the respiratory system.
Slide 4: Management Team
Management Team Deep expertise in respiratory diseases & drug delivery technology across all stages of development healthcare and life sciences leadership experience e Former Chief Commercial Officer at Option Care Ted Raad — CEO & Director e Previously Chief Business Officer of Pulmatrix 20 years o
Slide 5: Credentialed Board of Directors
Credentialed Board of Directors Board of directors with extensive experience in public and private life sciences companies Michael J. Higgins — Chairman e Entrepreneur-in-residence at Polaris Partners and Board Member of Genocea, Voyager, Kindex, Madauder and Sea Pharmaceuticals e Former SVP, COO, a
Slide 6: PULM (NASDAQ) Investment Highlights
PULM (NASDAQ) Investment Highlights e Proprietary iSPERSE platform technology that seeks to optimize pharmacokinetics and pharmacology in respiratory and non-respiratory therapeutics e Ascalable platform with applicability across drug classes and dry-powder delivery devices to support pipeline devel
Slide 7: iSPERSE Enabled Pipeline With Multiple Potential Milestones
iSPERSE Enabled Pipeline With Multiple Potential Milestones aaa, rar [ae [om [or] or] ca [os [oe [oon [os [oe PUR1800 Acute Exacerbations in Chronic “4 Ph1b Top Obstructive Pulmonary Disease i | Line Dat: NSKI (AECOPD) ine Data i Ph2 (POC) Top Line ae . aa Acute Migraine | tae beta pre Data anticipa
Slide 8: iSPERSE
ISPERSE Small Dense and Dispersible Engineered Dry Powder Proprietary Technology
Slide 9: iSPERSE Platform
iSPERSE Platform iSPERSE Enables Sick Patients to Get More Effective Doses (e.g., metered-dose, reservoir, capsule or blister-based inhalers) / flow for penetration deep into lung, based ® ams) with high ae ze a aftemar effects with improved P range \ Pp Sula \ 4m pharmacokinetics profile compared t
Slide 10: Pulmazole
Pulmazole Inhaled Antifungal Cipla Worldwide Development & Commercial Partnership Inhaled Itraconazole to Treat Allergic Bronchopulmonary Aspergillosis (ABPA) in Patients with Asthma iSPERSE enables itraconazole delivery to the lung, providing Pulmazole potential to address the underlying cause of d
Slide 11: Pulmazole: Potential to Change the Standard of Care for ABPA
Pulmazole: Potential to Change the Standard of Care for ABPA Phase 1/1b study successfully met all endpoints Demonstrated safety and tolerability of Pulmazole administered up to 14 days JS ~100—400 fold lower plasma exposure over 24 hours than expected with oral Sporanox ~50 llungiEtpoaure ~85 Boe n
Slide 12: Pulmazole Development Plan Builds Upon Clinical Precedent
Pulmazole Development Plan Builds Upon Clinical Precedent of Oral Itraconazole Improvement of FEV, in ABPA Oral itraconazole outcomes demonstrated in clinical literature tT NEW ENGLAND JOURNAL of MEDICINE H Journal of Clinical Immunology : Expert Review of Respiratory Medicine 2000, Stevens et al. i
Slide 13: Pulmazole: Phase 2b Study Intended to Demonstrate Proof of Concept
Pulmazole: Phase 2b Study Intended to Demonstrate Proof of Concept in Patients with Asthma and ABPA Successful FDA Type C meeting enables Ph2b study anticipated start in Q1 2023 Patient Profile AA Patients (MIF, ages 18-80) with confirmed asthma and ABPA Bahai placebo-controlled ole ae 8) Patients a
Slide 14: Pulmazole: $1.5B Peak Net Revenue Potential in the U.S.
Pulmazole: $1.5B Peak Net Revenue Potential in the U.S. Anticipated increase of first-line concomitant use with oral steroids drives the revenue forecast 65% ~1.3B Net ~200M U.S. ABPA Asthma Revenue U.S. Other Indications 30% Current Use of Antifungal 1st Line Future Use of Antifungal ‘st Line Xolai
Slide 15: PUR3100
PUR3100 Inhaled Dihydroergotamine (DHE) for Treatment of Acute Migraine (QM Significant unmet need in a large market represents Ks=4) ~$575M U.S. peak net revenue opportunity’ Lung delivery offers many potential advantages including fast acting pain relief and symptom control with a favorable tolera
Slide 16: PUR3100: Acute Treatment of Migraine
PUR3100: Acute Treatment of Migraine: Large underserved market Large Market >1 billion worldwide >38 million U.S. Affects 3x’s more women than men a) Large Unmet Medical Need 75% of patients not actively treated with Rx’s due to poor efficacy 80% of patients on Rx’s would try new therapies PULMATRIX
Slide 17: Inhaled DHE Therapy Potential Advantages
y Inhaled DHE Therapy Potential Advantages ‘s Want? What Pati Fast onset of action : Migraine upon : 24+ hourheadache : Inhaled preferred’ : Absence of: through early T,,,, : awakening, quickto : relief through H over intranasal, : nausea, lethargy, and sustained : peek intensity, rescue : sustained
Slide 18: PUR3100 Pharmacokinetics Compare Favorably With MAP0004
PUR3100 Pharmacokinetics Compare Favorably With MAP0004 Dog inhaled kinetics predicts human inhaled kinetics PUR3100 achieves similar pharmacokinetics ~< to MAP0004 in the dog All PUR3100 doses as predicted < by dog data Dose Normalized = Fa | PULMATRixX MAP0004 dog pharmacokinetics MAP0004 Dog’ 5.0
Slide 19: All PUR3100 Doses are Anticipated to Be in Therapeutic Window
All PUR3100 Doses are Anticipated to Be in Therapeutic Window Orally inhaled DHE (MAP0004) has a superior profile to other DHE — “Al e Blue arrows indicate modelled C,,,,, for proposed PUR3100 clinical nominal doses of 0.5, 1 and 1.5mg 100,000 >50% Emesis Bay a m 9 = Fi i i erin Fine particle dose e
Slide 20: PUR3100 Initial Phase 1 Clinical Study
PUR3100 Initial Phase 1 Clinical Study to Evaluate Safety, Leienuieini sh ang Pharmacokinetics Intravenous DHE _ 4 (Go) Initial Phase 1 Study IV DHE or 1 of 4 doses of PUR3100 Dose 1 PUR3100 with matching placebo (n=8) Assessment of safety, tolerability, and PK after administration of single dose nt
Slide 21: PUR3100 Ph2 Dose Confirmation Study
PUR3100 Ph2 Dose Confirmation Study Intended to Demonstrate Proof of Concept and Enable Pivotal Study ACY ¢ ) T uay rt Phase 2-Dose Confirmation Randomized Double-blind Placebo-Controlled Study in Otherwise Healthy Patients with Migraine e Patients provided with dose to administer at home during nex
Slide 22: PUR3100: $575M Peak Net Revenue Potential at LOE in the U.S.
PUR3100: $575M Peak Net Revenue Potential at LOE in the U.S. Physician and Patient Feedback Payer Feedback % of patients on triptan experiencing 40% | a suboptimal response % of patients ranking “starts to show 7 y improvement by 30 minutes” as the | 44% oy 2 generic treatment failures required per
Slide 23: PUR1800
PUR1800 Inhaled p38, Syk, Src Kinase Inhibitor with Potential for Treating AECOPD NSKI Portfolio In-Licensed from Janssen, Including RV1162 RV1162 Reformulated Into iSPERSE Enabled PUR1800 PUR1800 potentially represents up to ~$2.4B' peak net revenue opportunity in the U.S. as an inhaled non-steroid
Slide 24: Limited Efficacy in Standard of Care for AECOPD
Limited Efficacy in Standard of Care for AECOPD Moderate-to-Severe Exacerbations Significant unmet need exists in AECOPD with underlying infection and/or steroid resistance Noninfectious Bacterial Acute Exacerbation in COPD (AECOPD) Etiology Bacterial & Viral Fa | PULMATRIiX Steroids are standard of
Slide 25: Narrow Spectrum Kinase Inhibitors (NSKI)
Narrow Spectrum Kinase Inhibitors (NSKI) Block steroid-resistant inflammation and lung remodeling processes Treat Steroid-Resistant Inflammation e Inhibit p38 MAP kinases (p38MAPK) to restore steroid sensitivity and reduce inflammation e Block inflammatory action of Src, which promotes cytokine prod
Slide 26: RV1162 (NSKI) Reduces Steroid-Resistant Inflammation in Preclinical Models
RV1162 (NSKI) Reduces Steroid-Resistant Inflammation in Preclinical Models RV1162 reduces steroid insensitive, tobacco smoke-induced inflammation and restores steroid efficacy e Verified kinase target engagement and _ 3 inhibition with similar potency across p38, ay tr 1 I 1 Src and Syk kinases £ e
Slide 27: PUR1800 Phase 1b Trial in Stable COPD Preliminary Results
PUR1800 Phase 1b Trial in Stable COPD Preliminary Results ( ctiy >( C Randomized, double-blind, 3-way crossover study; 3 Dose Groups (2 active, 1 placebo) with 15 pts. 14 days of daily dosing, with 28-day crossover and 28-day follow-up 7 Endpoints Safety & Tolerability PUR1800 PUR1800 | (eoelva) (so
Slide 28: Potential Phase 2 Exploratory Study in AECOPD
Potential Phase 2 Exploratory Study in AECOPD Pulmatrix intends to pursue partnership opportunities to advance a PUR1800 Phase 2 study *) Evaluate Time to resolution of ¢ = Duration of therapy symptoms £ * Potential endpoints Treatment failure rate 3 . " Pts. with COPD g Safety and tolerability FEV,
Slide 29: PUR1800: $2.4B in U.S. Peak Revenue Potential
PUR1800: $2.4B in U.S. Peak Revenue Potential e ~16M COPD patients in the U.S. mectnencOnton Expected e 77% experience at least one exacerbation annually PUR1800 0% ~35% e ~18M moderate-to-severe AECOPD episodes (+ oral corticosteroids and/or antibiotics) i ] annually in U.S. Oral Corticosteroids +
Slide 30: Chronic Toxicology Pathology Results Support Potential Expansion
Chronic Toxicology Pathology Results Support Potential Expansion Into Chronic Treatment of Pulmonary Disease (ex. COPD, IPF, Asthma) Severe Asthma on ; ~10M Adults e Nopro ressio! the C in US? from 28-Day re (50% of Adult Asthma) Rare Disease <100K in US# AECOPD 18M Moderate to Severe Acute Exacerba
Slide 31: Appendix
Appendix
Slide 32: Glossary of Terms
Glossary of Terms 505(b)(2) FDA Regulatory Pathway for Drug Approval IgG Immunoglobulin G Antibodies ABPA Allergic Bronchopulmonary Aspergillosis IND Investigational New Drug AECOPD Acute Exacerbations in Chronic Obstructive Pulmonary Disease IP Intellectual Property BAL Bronchoalveolar Lavage LPS L